Adagene Inc. (ADAG)

Name: Adagene Inc. (ADAG) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Adagene Inc. (ADAG)

Stock Card

$3.68

$-0.22 (-5.64%)

As on 28-Aug-2026 16:00EDT

Market cap

$247 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

2.9

Div. Yield

0 %

Adagene (ADAG) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 3.66 High: 3.89

52 Week Range

Low: 1.30 High: 4.85

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.3 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

1.1
Debt to Equity

0.2
Book Value

$0.9
EPS

$-0.5
Face value

--
Shares outstanding

67,143,344

6 Years Aggregate

CFO

$-181.43 Mln

EBITDA

$-226.93 Mln

Net Profit

$-220.54 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Adagene (ADAG)	94.7	4.2	-8.0	68.0	45.1	-26.3	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022
Adagene (ADAG)	-5.0	3.0	45.7	-83.6
S&P Small-Cap 600	4.0	7.0	13.9	-17.4
BSE Sensex	9.1	8.1	18.7	4.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Adagene (ADAG)	3.7	247.1	7.7	-17.6	-49,331.1	-41	--	2.9
Arrowhead Pharmaceuticals (ARWR)	84.9	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Cytokinetics Inc (CYTK)	72.1	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.5	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	105.4	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	351.5	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	533.8	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	600.7	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	344.8	9,625.4	0.0	-339.1	--	-30.6	--	7.6
Protagonist Therapeutics (PTGX)	144.3	9,339.4	282.0	82.9	-28.6	11.4	140.1	11.5

Shareholding Pattern

View Details

About Adagene (ADAG)

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human... anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China. Read more

Co- Founder, Chairman, CEO and President of R&D

Dr. Peter P. Luo Ph.D.
Co- Founder, Chairman, CEO and President of R&D

Dr. Peter P. Luo Ph.D.
Headquarters

Suzhou
Website

https://www.adagene.com

FAQs for Adagene (ADAG)

What is the current share price of Adagene Inc (ADAG) Today?

The share price of Adagene Inc (ADAG) is $3.68 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Adagene Inc (ADAG) has given a return of 45.09% in the last 3 years.